Three economists explore the viability of a UN-backed one-stop licensing ‘hub’ for making essential, often life-saving biotherapeutics and vaccines both affordable and more widely available.
- Professor of industrial economics, EM Lyon Business School
Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
Des accords de licence entre les groupes pharmaceutiques et le Medicines Patent Pool, en coopération avec l’OMS, pourraient accélérer l’accès aux doses pour les pays les plus pauvres.
Contact Bruno for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Website
- Article Feed
- ORCID
- Joined


